Medtronic (MDT) Tops Q4 Earnings Estimates, Announces 'Largest Ever' R&D Spending to Support Growth
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Medtronic, Inc. (MDT) PT Raised to $147 at Oppenheimer
May 28, 2021 9:50 AM EDTOppenheimer analyst Steven Lichtman raised the price target on Medtronic, Inc. (NYSE: MDT) to $147.00 (from $134.00) while maintaining an Outperform rating following fourth quarter results.
The analyst commented, "On its F4Q21 call, MDT highlighted continued COVID-19 procedural recovery and solid sales outlook. Key updates: 1) monthly... More
Medtronic (MDT) Tops Q4 EPS by 8c, Offers FY22 Guidance, Raises Dividend
May 27, 2021 6:46 AM EDT(Updated - May 27, 2021 6:50 AM EDT)
Medtronic (NYSE: MDT) reported Q4 EPS of $1.50, $0.08 better than the analyst estimate of $1.42. Revenue for the quarter came in at $8.2 billion versus the consensus estimate of $8.14 billion.
GUIDANCE:
Medtronic sees 2022 EPS of $5.60-$5.75, versus the consensus of $5.72.
The company expects revenue growth in its fiscal year 2022 to approximate 9 percent on an organic basis. If current exchange rates hold, revenue growth in fiscal year 2022 would be positively affected by approximately $400 to $500 million."Our fiscal 2022 revenue guidance that we... More